Scott Holmes - Ascendis Pharma Head Endocrinology
| ASND Stock | USD 136.00 0.32 0.23% |
Executive
Scott Holmes is Head Endocrinology of Ascendis Pharma AS
| Address | Tuborg Boulevard 12, Hellerup, Denmark, 2900 |
| Phone | 45 70 22 22 44 |
| Web | https://ascendispharma.com |
Ascendis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2792) % which means that it has lost $0.2792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.47, whereas Return On Tangible Assets are forecasted to decline to (0.62). At present, Ascendis Pharma's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 374.1 M, whereas Non Current Assets Total are forecasted to decline to about 79.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Holly Hobson | United Therapeutics | N/A | |
| Pr MD | Apellis Pharmaceuticals | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Scott Gangloff | Akero Therapeutics | 50 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| David JD | Akero Therapeutics | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Colin Love | Replimune Group | 66 | |
| Andrew Schwendenman | Replimune Group | 48 | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| John Soglia | Nuvalent | N/A | |
| Michael CPA | Blueprint Medicines Corp | 52 | |
| Mike JD | Pliant Therapeutics | 51 | |
Management Performance
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.28 |
Ascendis Pharma AS Leadership Team
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael LLM, Chief VP | ||
| Birgitte MD, Sr Affairs | ||
| Stina MD, Executive Oncology | ||
| Scott Holmes, Head Endocrinology | ||
| Timothy Lee, Director Relations | ||
| Nyssa Noyola, Vice Management | ||
| Jens Okkels, VP Devel | ||
| Flemming Jensen, Senior Vice President Product Supply | ||
| Scott Smith, CFO, Senior Vice President | ||
| Mads Bodenhoff, Senior Officer | ||
| Jan Mikkelsen, CEO and President Member of Executive Board and Executive Director | ||
| Joseph Kelly, Head Endocrinology | ||
| Lotte Sonderbjerg, Sr Officer | ||
| Peter Rasmussen, Principal Accounting Officer and VP of Fin. | ||
| Kennett Sprogoe, Executive Development |
Ascendis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascendis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.54) % | ||||
| Operating Margin | (3.70) % | ||||
| Current Valuation | 8.32 B | ||||
| Shares Outstanding | 59.76 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 99.27 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| Price To Earning | (9.10) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.82) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.